Cargando…

A Review of the Role of the Antiplatelet Drug Ticagrelor in the Management of Acute Coronary Syndrome, Acute Thrombotic Disease, and Other Diseases

P2Y12 inhibitors, including aspirin, are key components of dual-antiplatelet therapy (DAPT), which is the optimal therapeutic strategy for preventing arterial thrombosis in patients with acute coronary syndromes (ACS) who underwent stent implantation. Ticagrelor is a cyclopentyl-triazole pyrimidine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tao, Luyuan, Ren, Shijia, Zhang, Li, Liu, Wenhua, Zhao, Yi, Chen, Changgong, Mao, Xiang, Chen, Zili, Gu, Xingjian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2022
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121774/ https://www.ncbi.nlm.nih.gov/pubmed/35570383 http://dx.doi.org/10.12659/MSM.935664

Ejemplares similares

Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor
por: Birkeland, Kade, et al.
Publicado: (2010)

Risk Factors of Ischemia Reperfusion Injury After PCI in Patients with Acute ST-Segment Elevation Myocardial Infarction and its Influence on Prognosis
por: Zhang, Li, et al.
Publicado: (2022)

Ticagrelor: An investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome
por: Abergel, Eitan, et al.
Publicado: (2010)

Ticagrelor: An emerging oral antiplatelet agent
por: Juneja, Shivani, et al.
Publicado: (2013)

The effect of antiplatelet drug on coronary endothelial and microvascular function: comparison with ticagrelor and clopidogrel
por: Choi, Woong Gil, et al.
Publicado: (2021)

Metabolism of ticagrelor in patients with acute coronary syndromes
por: Adamski, Piotr, et al.
Publicado: (2018)

Ticagrelor-associated thrombotic thrombocytopenic purpura
por: Doğan, Ali, et al.
Publicado: (2017)

Comparing the effectiveness and safety of dual antiplatelet with ticagrelor or clopidogrel in elderly Asian patients with acute myocardial infraction
por: Yeh, Jong-Shiuan, et al.
Publicado: (2023)

Effect of ticagrelor and clopidogrel dual antiplatelet therapy on MPVLR, MAADP, and AA inhibition rate in acute coronary syndrome patients after percutaneous coronary intervention
por: Gao, Song-Tao, et al.
Publicado: (2023)

Ticagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromes
por: Lombo, Bernardo, et al.
Publicado: (2011)

Ticagrelor: The first approved reversible oral antiplatelet agent
por: Goel, Divya
Publicado: (2013)

Critical appraisal of ticagrelor in the management of acute coronary syndrome
por: Nawarskas, James J, et al.
Publicado: (2011)

Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor
por: Davis, Estella M, et al.
Publicado: (2013)

Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial
por: Li, Pan, et al.
Publicado: (2016)

Ticagrelor Monotherapy After 3-Month Dual Antiplatelet Therapy in Acute Coronary Syndrome by High Bleeding Risk: The Subanalysis From the TICO Trial
por: Lee, Yong-Joon, et al.
Publicado: (2021)

Novel antiplatelet agents in the prevention of cardiovascular complications – focus on ticagrelor
por: Marczewski, Margaret M, et al.
Publicado: (2010)

Dyspnoea management in acute coronary syndrome patients treated with ticagrelor
por: Parodi, Guido, et al.
Publicado: (2015)

Risk of Major Bleeding With Potent Antiplatelet Agents After an Acute Coronary Event: A Comparison of Ticagrelor and Clopidogrel in 5116 Consecutive Patients in Clinical Practice
por: Mullen, Liam, et al.
Publicado: (2021)

Optimal strategy of switching from clopidogrel to ticagrelor in Chinese acute coronary syndrome patients with complicated coronary artery disease: the switching from clopidogrel to ticagrelor (SHIFT-CACS) study
por: Yao, Ying, et al.
Publicado: (2019)

Walking the Line with Ticagrelor: Meta-Analysis Comparing the Safety and Efficacy of Ticagrelor Monotherapy after a Short Course of Ticagrelor-Based Dual Antiplatelet Therapy versus Standard Therapy in Complex Percutaneous Coronary Intervention
por: Condello, Francesco, et al.
Publicado: (2021)

Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients With Diabetes
por: Alexopoulos, Dimitrios, et al.
Publicado: (2013)

Ticagrelor as an Alternative Antiplatelet Therapy in Cardiac Patients Non-Sensitive to Aspirin
por: Khan, Hamzah, et al.
Publicado: (2020)

Comparison of ticagrelor with clopidogrel on quality of life in patients with acute coronary syndrome
por: Moon, Hyeyeon, et al.
Publicado: (2021)

Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction
por: Scanavini-Filho, Marco Antonio, et al.
Publicado: (2022)

Hospital‐Level Variation in Ticagrelor Use in Patients With Acute Coronary Syndrome
por: Ozaki, Aya F., et al.
Publicado: (2022)

Effect of altitude on ticagrelor-induced dyspnea in patients with acute coronary syndrome
por: Kocabay, Gonenc, et al.
Publicado: (2023)

Ticagrelor versus Clopidogrel in Patients with Severe Renal Insufficiency Undergoing PCI for Acute Coronary Syndrome
por: Chen, Yunxian, et al.
Publicado: (2022)

Prevalence of adverse events during ticagrelor versus clopidogrel treatment and its association with premature discontinuation of dual antiplatelet therapy in East Asian patients with acute coronary syndrome
por: Kang, Min Gyu, et al.
Publicado: (2022)

Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome
por: Xie, Zhi-Jiang, et al.
Publicado: (2021)

Cost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes in Canada
por: Grima, Daniel T, et al.
Publicado: (2014)

Long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand
por: Yamwong, Sukit, et al.
Publicado: (2014)

Determinants of high platelet reactivity in patients with acute coronary syndromes treated with ticagrelor
por: Adamski, Piotr, et al.
Publicado: (2019)

Effects of switching ticagrelor to clopidogrel on cardiovascular outcomes in patients with acute coronary syndrome
por: Liu, Lin, et al.
Publicado: (2018)

Ticagrelor after Acute Coronary Syndrome: One For All or Part of Personalized Medicine?
por: Akin, Ibrahim, et al.
Publicado: (2022)

Prediction of residual ischemic risk in ticagrelor-treated patients with acute coronary syndrome
por: Zou, Yuting, et al.
Publicado: (2022)

Cost-Effectiveness Comparison between Ticagrelor and Clopidogrel in Acute Coronary Syndrome in Iran
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2023)

Clinical effect of ticagrelor administered in acute coronary syndrome patients following percutaneous coronary intervention
por: LU, YANJIAO, et al.
Publicado: (2016)

Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients With Acute Coronary Syndrome: A Meta-Analysis
por: Dai, Lulu, et al.
Publicado: (2022)

Antiplatelet Therapy Aims and Strategies in Asian Patients with Acute Coronary Syndrome or Stable Coronary Artery Disease
por: Tam, Chor-Cheung, et al.
Publicado: (2022)

Systemic Design and Evaluation of Ticagrelor-Loaded Nanostructured Lipid Carriers for Enhancing Bioavailability and Antiplatelet Activity
por: Son, Gi-Ho, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_90bvhmubj78v50p7p83lt31d78